Tysabri 300 MG/15 ML vial 15ML
Ended Awarded
- Contract number
- SPE2DR26FCRK6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,484
Award facts
- Contract value 100% obligated
- $21,483.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $21,483.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 ml vials. This firm fixed-price delivery order, awarded on November 20, 2025, with an ultimate completion date of December 12, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's newly established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036.
DMS Pharmaceutical Group's selection as a prime vendor under the $30.3 billion PPV-G GEN V acquisition strategy positions the company as a critical supplier for Department of Defense healthcare operations worldwide. The contractor's extensive product portfolio spans branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, enabling it to fulfill the diverse pharmaceutical requirements of military healthcare facilities. This delivery order for TYSABRI, an immunosuppressant biologic agent, reflects the contractor's established capability to supply specialized pharmaceutical products to support recurring medical supply needs across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRK6?
SPE2DR26FCRK6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FCRK6 worth?
The government has obligated $21,484 on SPE2DR26FCRK6.
Is contract SPE2DR26FCRK6 an order under another contract?
Yes. SPE2DR26FCRK6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRK6 competed?
The extent of competition for SPE2DR26FCRK6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award